Sequential test to determine the ED50 of remazolam besylate-induced loss of consciousness in gynecological day surgery patients

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100052647

Enrollment

Unknown

Registered

2021-11-03

Start date

2021-11-08

Completion date

Unknown

Last updated

2022-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Experimental group:remimazolm

Eligibility

Sex/Gender

Female

Age

35 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Select gynecological patients who undergo elective hysteroscopy in Weifang People's Hospital; 2. ASA classification I-II; 3. Sign the informed consent for anesthesia.

Exclusion criteria

Exclusion criteria: 1. Patients who are allergic to benzodiazepines and any components of this product; 2. Patients with myasthenia gravis; 3. Patients with schizophrenia and severe depression; 4. Pathological obesity/obstructive sleep apnea; 5. Acute upper respiratory tract infection; 6. Asthma attack period; 7. Uncontrolled severe hypertension; 8. Unstable angina; 9. Severe liver dysfunction; 10. Acute upper gastrointestinal bleeding with shock; 11. Severe anemia; 12. Gastrointestinal obstruction with retention of gastric contents; 13. Long-term sedative and analgesic drug use history and allergic history; 14. There are contraindications to anesthesia.

Design outcomes

Primary

Measure	Time frame
Loss of consciousness;	—

Secondary

Measure	Time frame
Changes in blood pressure and oxygenation;Adverse reactions;	—

Countries

China

Contacts

Public ContactJi Fanceng

Weifang People's Hospital

jifanceng@163.com+86 13563698838

Outcome results